Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Joseph Kim, Dana Backlund Cardin, Yu Shyr, Patricia LoRusso, S. Percy Ivy, Shumei Kato, Ulka N. Vaishampayan, Peter M. Glazer, Steven R. Grossman
Publikováno v:
The Oncologist
Lessons Learned Background Cediranib, a vascular endothelial growth factor receptor inhibitor, suppresses expression of BRCA1/2 and RAD51 inducing homologous recombination DNA repair deficiency (HRD) in several cancer cell lines and xenograft models
Autor:
Daizo Kaito, Mototsugu Shimokawa, Takenobu Gomyo, Jun Hakamata, Akio Suzuki, Takahiro Arai, Yasushi Ohno, Chiemi Hirose, Norihiko Funaguchi, Chizuru Sakai, Hitoshi Kawazoe, Koichi Minato, Hiroyuki Okura, Hisao Imai, Hirotoshi Iihara, Yukiyoshi Fujita, Shinnosuke Ikemura, Mie Kotake
Publikováno v:
The Oncologist
Background Olanzapine is an inexpensive and durable agent for the treatment of chemotherapy‐induced nausea and vomiting and is also superior to neurokinin‐1 receptor antagonists in the control of nausea. This study aimed to investigate the effica
Autor:
Florian Scotté, Luigi Celio, Yolanda Escobar, Alessandra Franceschetti, Karin Jordan, Danielle Bell, Matti Aapro, Richard Berman
Publikováno v:
Oncologist
Background Guideline-recommended antiemetic prophylaxis improves nausea and vomiting control in most patients undergoing chemotherapy. Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO) antiemeti
Autor:
William L. Bailey, Kathryn J. Ruddy, Lee S. Schwartzberg, Rebecca Clark-Snow, Thomas W. LeBlanc, Eric Roeland, Rudolph M. Navari, Luke M. Schmerold, Ryan D. Nipp, Ravi Potluri, Eros Papademetriou, Gary Binder
Publikováno v:
Oncologist
Purpose Chemotherapy-induced nausea and vomiting (CINV) contributes to avoidable acute care, a metric now tracked in Medicare's oncology outcome measure. CINV is preventable, yet guidelines are often not followed. We sought to quantify acute care inv
Autor:
Weishi Vivian Yuan, Richard Pazdur, Abhilasha Nair, Martha Donoghue, Patricia Keegan, Lisa Rodriguez, Kelie Reece
Publikováno v:
Oncologist
On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized
Autor:
Giada Rizzi, Lee S. Schwartzberg, Rebecca Clark-Snow, Ekaterine Arkania, Richard J. Gralla, Rudolph M. Navari, Matti Aapro, Daniel Voisin, Rita Wickham, Irena Radyukova, Kamal Patel, Eric Roeland
Publikováno v:
The Oncologist
Background NEPA, a combination antiemetic of a neurokinin‐1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT3RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution co
Autor:
Toshinobu Hayashi, Mototsugu Shimokawa, Keisuke Aiba, Hitoshi Kawazoe, Kazuo Tamura, Toshiaki Saeki, Hirotoshi Iihara
Publikováno v:
The Oncologist
Background We previously reported the results of a prospective study of chemotherapy‐induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin‐based chemotherapy and were selected from a nationwide registry of those sche
Autor:
Min Hua Jen, Daniel Shao-Weng Tan, Valentina Boni, Lisa M. Hess, Lori J. Wirth, Caroline E. McCoach, Erminia Massarelli, Elizabeth Olek, Jennifer Kherani, Bruce G. Robinson, Vivek Subbiah
Publikováno v:
Oncologist
Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease-related diarrhea, primarily because of non-RET kinase inhibition. We report diarrhea and other patient-reported outcomes (
Publikováno v:
The oncologist. 26(12)
Background Locally advanced basal cell cancer is a rare and challenging clinical problem. Historically, these patients were treated with aggressive surgery or radiotherapy. Most sporadic basal cell carcinomas have somatic mutations in the hedgehog pa
Autor:
Suzanne F. Jones, Howard A. Burris, Joseph Stilwill, Dianna Shipley, Cindy Jacobs, John D. Hainsworth, David R. Spigel, Brian Hemphill, Kent C. Shih, Patrick J. Ward, Ray D. Page, Tarek Mekhail, Michael McCleod, Robert C. Whorf, David M. Waterhouse
Publikováno v:
The Oncologist. 24:e1409-e1416
Background This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with previously unt